Article
Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development
2021-03-14
Abstract excerpt
<h4>ABSTRACT</h4> Pre-existing immune responses towards adenoviral vector limit the use of a vector based on particular serotypes and its clinical applicability for gene therapy and/or vaccination. Therefore, there is a significant interest to vectorize novel adenoviral types that have low seroprevalence in the human population. Here, we describe the discovery and vectorization of a chimeric human adenovirus, whi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f067f390-60e6-5732-92de-78cdc1060007
- DOI
- 10.1101/2021.03.11.435055
